Evofem's SOLOSEC submitted for regulatory approval in the UAE
Marks first international filing for Evofem’s single-dose oral treatment
Marks first international filing for Evofem’s single-dose oral treatment
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
Subscribe To Our Newsletter & Stay Updated